Consuelo Arteaga de Murphy1, Filip Gemmel, Jenny Balter. 1. Departamento de Medicina Nuclear, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga, Delegación Tlalpan, Mexico.
Abstract
OBJECTIVE: For several decades Ga citrate, technetium-99m ((99m)Tc) or (111)In-labelled leukocytes have been used for imaging the inflammatory process. Unfortunately, these radiopharmaceuticals are not infection-specific markers. In preclinical settings, radiolabelled antimicrobial peptides (AMPs), such as UBI 29-41 seem to be highly infection-specific and even high doses of these peptides have shown neither toxicity nor side effects in animals. METHODS: In this study we present data of a recent clinical trial carried out with the (99m)Tc labelled antimicrobial peptide UBI 29-41 ((99m)Tc-UBI 29-41) regarding its sensitivity, specificity, and accuracy in detecting various types of infections in 148 patients. The outcome of the trial with (99m)Tc-UBI 29-41 is compared with that of five other trials. RESULTS: Preparation of (99m)Tc-UBI 29-41 as a kit formulation is an easy, rapid, and reproducible process, and the tracer is very well tolerated by patients. The radiopharmaceutical has proven to be very stable and after injection into patients the biodistribution (renal clearance) and dosimetry seem to be favourable over other infection imaging radiopharmaceuticals. In this preliminary human study, patients with fever of unknown origin, osteomyelitis, diabetic foot, prosthesis infection, septic arthritis, or bacteraemia were successfully imaged with (99m)Tc-UBI 29-41 scintigraphy. CONCLUSION: (99m)Tc-UBI 29-41 is a promising agent for the specific detection of infections in humans because of its high sensitivity (96.3%), specificity (94.1%), and accuracy (95.3%) with high positive predictive (95.1%) and negative predictive values (95.5%).
OBJECTIVE: For several decades Ga citrate, technetium-99m ((99m)Tc) or (111)In-labelled leukocytes have been used for imaging the inflammatory process. Unfortunately, these radiopharmaceuticals are not infection-specific markers. In preclinical settings, radiolabelled antimicrobial peptides (AMPs), such as UBI 29-41 seem to be highly infection-specific and even high doses of these peptides have shown neither toxicity nor side effects in animals. METHODS: In this study we present data of a recent clinical trial carried out with the (99m)Tc labelled antimicrobial peptide UBI 29-41 ((99m)Tc-UBI 29-41) regarding its sensitivity, specificity, and accuracy in detecting various types of infections in 148 patients. The outcome of the trial with (99m)Tc-UBI 29-41 is compared with that of five other trials. RESULTS: Preparation of (99m)Tc-UBI 29-41 as a kit formulation is an easy, rapid, and reproducible process, and the tracer is very well tolerated by patients. The radiopharmaceutical has proven to be very stable and after injection into patients the biodistribution (renal clearance) and dosimetry seem to be favourable over other infection imaging radiopharmaceuticals. In this preliminary human study, patients with fever of unknown origin, osteomyelitis, diabetic foot, prosthesis infection, septic arthritis, or bacteraemia were successfully imaged with (99m)Tc-UBI 29-41 scintigraphy. CONCLUSION: (99m)Tc-UBI 29-41 is a promising agent for the specific detection of infections in humans because of its high sensitivity (96.3%), specificity (94.1%), and accuracy (95.3%) with high positive predictive (95.1%) and negative predictive values (95.5%).
Authors: Filip Gemmel; Hans Van den Wyngaert; Charito Love; M M Welling; Paul Gemmel; Christopher J Palestro Journal: Eur J Nucl Med Mol Imaging Date: 2012-02-24 Impact factor: 9.236
Authors: Mick M Welling; Clarize M de Korne; Silvia J Spa; Danny M van Willigen; Albertus W Hensbergen; Anton Bunschoten; Nikolas Duszenko; Wiep Klaas Smits; Meta Roestenberg; Fijs W B van Leeuwen Journal: ACS Infect Dis Date: 2019-05-02 Impact factor: 5.084
Authors: María F De la Cerda-Vargas; José Antonio Candelas Rangel; Elizabeth Meza Mata; Araceli Ramírez-Cárdenas; Bayron A Sandoval-Bonilla Journal: Surg Neurol Int Date: 2020-12-16
Authors: Thomas Ebenhan; Olivier Gheysens; Hendrick Gert Kruger; Jan Rijn Zeevaart; Mike Machaba Sathekge Journal: Biomed Res Int Date: 2014-08-27 Impact factor: 3.411